Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Peripheral T-Cell Lymphoma (PTCL) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Access All Programs
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Neha Mehta-Shah, MD, MSCI

    Neha Mehta-Shah, MD, MSCI

    Associate Professor of Medicine
    Division of Oncology (Cancer, Bone Marrow Transplant)
    Siteman Cancer Center
    WashU Medicine
    Washington University
    St. Louis, Missouri


    Related Videos

    Can you discuss the challenges of classifying subtypes of PTCL—especially PTCL-TFH—and how to optimize biomarker-based diagnosis of this condition to ensure actionable and precision-based therapies are identified? Video

    Can you discuss the challenges of classifying subtypes of PTCL—especially PTCL-TFH—and how to optimize biomarker-based diagnosis of this condition to ensure actionable and precision-based therapies are identified?

    Once the diagnosis of PTCL-TFH lymphoma is established in a patient, what does the treatment pathway and standard-of-care protocol look like for persons with this variant? Video

    Once the diagnosis of PTCL-TFH lymphoma is established in a patient, what does the treatment pathway and standard-of-care protocol look like for persons with this variant?

    How did PRIMO’s strong duvelisib results in PTCL-TFH—better response, survival—impact TERZO trial design, dosing strategy, and outcome goals? Video

    How did PRIMO’s strong duvelisib results in PTCL-TFH—better response, survival—impact TERZO trial design, dosing strategy, and outcome goals?

    Given the improved clinical outcomes observed in the PRIMO trial, how did these results and specific signals translate into NCCN recommendations? Video

    Given the improved clinical outcomes observed in the PRIMO trial, how did these results and specific signals translate into NCCN recommendations?

    Can you explain to specialists who have not yet protocolized duvelisib into their strategy for R/R PTCL-TFH exactly in whom, when, and at what dose you incorporate duvelisib into your treatment plan? Video

    Can you explain to specialists who have not yet protocolized duvelisib into their strategy for R/R PTCL-TFH exactly in whom, when, and at what dose you incorporate duvelisib into your treatment plan?

    How did duvelisib, a delta-gamma PI3K inhibitor with known activity in hematological malignancies, emerge as an important therapy of interest for PTCL-TFH? Video

    How did duvelisib, a delta-gamma PI3K inhibitor with known activity in hematological malignancies, emerge as an important therapy of interest for PTCL-TFH?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED